Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,618.00-0.20%ETH$2,695.89-0.68%GOLD$4,191.90+0.84%OIL$89.82+0.44%
Smart Investors Daily
SID Premium
NE

NASDAQ · NEUP

Neuphoria Therapeutics Inc.

Healthcare · Medical - Pharmaceuticals

$3.45

Up+$0.00 (+0.00%)

Updated Oct 6, 2026, 8:37 PM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.4M
P/E ratio
-0.02
Dividend yield
0.00%
52-week range
$3.19 – $5.53
Volume
15.46K
Avg. volume
1.58M

Price performance · NEUP

NEUP price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

NEUP closed at $3.45 after 20 trading sessions, down 8.00% for the selected period.

Last close
$3.45
Period change
-8.00%
Period low
$3.45
Period high
$3.80
Daily close
View OHLC price history
NEUP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$3.45$3.50$3.43$3.4515.46K
Oct 2, 2026$3.51$3.59$3.45$3.4712.58K
Oct 1, 2026$3.5253$3.54$3.50$3.5114.3K
Sep 30, 2026$3.5995$3.615$3.53$3.5610.39K
Sep 29, 2026$3.64$3.65$3.57$3.5715.03K
Sep 28, 2026$3.67$3.69$3.65$3.652.88K
Sep 25, 2026$3.67$3.67$3.65$3.651.32K
Sep 24, 2026$3.67$3.6995$3.65$3.655.42K
Sep 23, 2026$3.69$3.755$3.66$3.6815.48K
Sep 22, 2026$3.73$3.77$3.71$3.7356.73K
Sep 21, 2026$3.69$3.79$3.68$3.7117.92K
Sep 18, 2026$3.712$3.8299$3.70$3.7021.58K
Sep 17, 2026$3.79$3.79$3.71$3.7155.31K
Sep 16, 2026$3.72$3.81$3.72$3.7436.79K
Sep 15, 2026$3.75$3.80$3.73$3.7817.69K
Sep 14, 2026$3.78$3.84$3.74$3.8012.52K
Sep 11, 2026$3.78$3.78$3.72$3.7323.04K
Sep 10, 2026$3.79$3.7925$3.70$3.7342.99K
Sep 9, 2026$3.795$3.8647$3.75$3.7518.61K
Sep 8, 2026$3.84$3.84$3.72$3.7522.6K

Latest NEUP news

The latest Smart Investors Daily articles mentioning NEUP.

Stock researchCompany · Overview

NEUP research

Overview

Company profile and research snapshot.

Company profile

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.00
Implied upside
—
Analysts
—
NEUP recent ratings
DateFirmRatingTarget
May 15, 2026HC Wainwright & Co.Neutral—
Dec 5, 2025HC Wainwright & Co.Buy—
Sep 11, 2025Maxim GroupBuy—
Aug 26, 2025HC Wainwright & Co.Buy—
Feb 4, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 24, 2026

Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development

OXFORD, United Kingdom and BURLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP) (“Scancell”, or the “Company”), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announced today that, further to its announcement on 23 July 2026 regarding the planned merger with Neuphoria Therapeutics Inc. (“Neuphoria”) and financing to conduct the registrational Phase 3

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By